Results 91 to 100 of about 17,592 (206)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Breast Cancer Research, 2019
Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens.
Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Giuseppina Sanna, Erica Moretti, Alessandro M. Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Antonio Bernardo, Angelo Martignetti, Emanuela Risi, Marta Pestrin, Luca Boni, Matteo Benelli, Laura Biganzoli, Angelo Di Leo, Luca Malorni   +19 more
doaj   +1 more source

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

Cancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou   +12 more
wiley   +1 more source

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice

Медицинский совет, 2019
Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities for the treatment of metastatic hormone receptor-positive (HRP+) HER2-negative (HER2-) breast ...
L. G. Zhukova, E. I. Khatkova, P. S. Feoklistova, K. S. Grechukhina, S. A. Smolin, E. A. Arutyunyan, E. M. Kolyago   +6 more
doaj   +1 more source

Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer [PDF]

Background: Data on exposure–response or exposure–toxicity relationships of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are limited and inconclusive.
Steeghs, N., Siebinga, H., Huitema, A. D.R., Jager, A., Buijs, S. M., Braal, C. L., Wortelboer, N., Koolen, S. L.W., Mathijssen, R. H.J.; id_orcid, Oomen-de Hoop, E.; id_orcid, Mohmaed Ali, M. I., Sonke, G. S., Konings, I. R., van Ommen-Nijhof, A.   +13 more
core   +1 more source

Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting

Cancer Medicine, Volume 15, Issue 6, June 2026.
US community oncology patients with dedifferentiated liposarcoma have heterogeneous profiles, treatments, and outcomes. The poor survival rates in this population suggest an unmet need for better therapeutics. ABSTRACT Introduction Clinical characteristics and outcomes of patients treated for dedifferentiated liposarcoma (DDLPS) at community oncology ...
James E. Butrynski, Bal Nepal, Chenxiao Hu, Jinhong Guo, Jennifer Han, Lisa Herms, Alyssa B. Klein, Stephen Stanhope, Elizabeth L. Stanley, Karen Todoroff, Paul Conkling   +10 more
wiley   +1 more source

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy

, 2019
While clinical responses to palbociclib have been promising, metastatic breast cancer remains incurable due to the development of resistance. We generated estrogen receptor-positive (ER+) and ER-negative (ER−) cell line models and determined their ...
Stephanie Vega, Lilibeth Lanceta, Alana Gipson, Rodolfo Garza-Morales, Jason Chesney, Jorge Gomez-Gutierrez, Kelly McMasters, Nadiia Lypova, Yoannis Imbert-Fernandez   +8 more
core   +1 more source

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background This retrospective series reports outcomes and prognostic factors for advanced chordoma (AC) treatment with molecular targeted therapies (MTTs) in different treatment lines. Methods This is a retrospective series of 57 patients with AC treated between 2004 and 2023 at one of seven participating sarcoma centres.
Astrid Lipplaa, Nadia Hindi, Pawel Teterycz, Robin J. Young, Ioannis Boukonavis, Josefina Cruz, Javier Martinez‐Trufero, Frank Speetjens, Wilco Peul, Robert J. P. van der Wal, Hans Gelderblom   +10 more
wiley   +1 more source

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

Journal of Global Oncology, 2019
PURPOSE: In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer.
Seock-Ah Im, Hirofumi Mukai, In Hae Park, Norikazu Masuda, Chikako Shimizu, Sung-Bae Kim, Young-Hyuck Im, Shoichiro Ohtani, Cynthia Huang Bartlett, Dongrui R. Lu, Shrividya Iyer, Yuko Mori, Ave Mori, Eric Gauthier, Richard S. Finn, Masakazu Toi   +15 more
doaj   +1 more source

Unveiling Candidate Markers for Drug Resistance or Synthetic Lethality in Cervical Cancer: Integrative Analysis of Genetic and Pharmacoprofiling

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Introduction Systemic cervical cancer management continues to be challenging. Numerous chemotherapies have been approved, but predicting response is difficult due to the lack of biomarkers. Here, we analyze the genetic and protein profiles of 20 cervical cancer cell lines (CCCLs) and explore their correlation with drug response patterns to ...
Suzy Scholl, Elaine Del Nery, Pierre Gestraud, Maral Halladjian, Elodie Girard, Adèle Soria, Elodie Anthony, Leanne De Koning, Nicolas Servant, Els Berns, Maud Kamal   +10 more
wiley   +1 more source

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Experimental Hematology & Oncology
Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its ...
Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener   +18 more
doaj   +1 more source